Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 6/20 | 0.63 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928870 | 0.86 | GRM5 (0.74) | GABRA5CXCR2GRM5CXCR1 | |
| SCHEMBL28703922 | 0.83 | CXCR2 (0.64) | CXCR2GRM5EPHX2CHRNB2CHRNA7 | |
| SCHEMBL1461093 | 0.83 | EPHX2 (0.56) | GABRA5CXCR2GRM5EPHX2GRN | |
| SCHEMBL13701697 | 0.82 | MAPT (0.62) | GABRA5CXCR2CXCR1 | |
| SCHEMBL6927893 | 0.81 | CXCR2 (0.68) | GABRA5CXCR2CXCR1 | |
| SCHEMBL13701718 | 0.81 | GRN (0.63) | GABRA5GRNSORT1 | |
| SCHEMBL246555 | 0.81 | GABRA5 (0.60) | GABRA5CXCR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL1091737 | 0.80 | MAOB (0.62) | CXCR2CHRNB2CHRNA7CHRNA4FFAR1 | |
| SCHEMBL1221922 | 0.80 | MAPT (0.63) | GABRA5CXCR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL13701799 | 0.79 | NNMT (0.58) | GABRA5CXCR2CXCR1GRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | GABRA5 26/4885CXCR2 2454/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.